trending Market Intelligence /marketintelligence/en/news-insights/trending/i1lnzywjimfdy6jkstrw0g2 content esgSubNav
In This List

Lundbeck, Takeda antidepressant more effective than placebo in phase 3 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Lundbeck, Takeda antidepressant more effective than placebo in phase 3 trial

H. Lundbeck A/S and Takeda Pharmaceutical Co. Ltd. said Trintellix was more effective in treating depression than placebo in a phase 3 trial.

The study, called NCT02389816, enrolled about 490 Japanese adults with major depressive disorder. Patients received either Trintellix, also known as vortioxetine, in 10-milligram or 20-milligram doses, or placebo. The main goal was change from baseline, using a certain rating scale, after eight weeks.

With the results, Denmark-based Lundbeck and Japan-based Takeda plan to proceed with Japanese regulatory filing for the drug later in 2018.

Vortioxetine, which is known Brintellix outside North America, is already approved in the U.S. and China.

Major depressive disorder, also known as clinical depression, affects about 300 million people globally.